News Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
2.19 ^USD	-0.45%		+12.89%	+93.81%

May. 08	Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results	May. 08	AQ
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	May. 05	CI
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76	May. 02	CI
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	Apr. 30	CI
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	Apr. 01	CI
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc	Mar. 06	CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update	23-08-10	AQ
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Context Therapeutics to Participate in Two August 2023 Investor Conferences	23-08-01	AQ
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update	23-06-13	AQ
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN	23-06-06	AQ
CONTEXT THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-02	AQ
Testicular Cancer Pipeline Assessment, FDA Approvals, Clinical Trials, Emerging Drugs, and Therapeutics Assessment 2023 \| Major Companies - Sanofi, Seagen Inc., BioNTech, Seagen, and Others	23-05-16	AQ
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting	23-04-24	AQ
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-22	AQ
CONTEXT THERAPEUTICS INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities (form 8-K)	23-03-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Context Therapeutics Inc. Nasdaq

Equities

US21077P1084

Summary

Filters